ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
ITM-91/ITM-94 is a first-in-class, peptide-based theranostic pair combining the radiotherapeutic compound ITM-91 (Debio 0228) ([177Lu]Lu-DPI-4452), with the diagnostic agent ITM-94 (Debio 0328) ([68Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CAIX). CAIX is a cell surface protein that plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion and metastasis. In September 2024, ITM gained the exclusive worldwide license from Debiopharm for the development and commercial rights of ITM-91/ITM-94. The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement.
In the now initiated Part D of the trial, ITM-94 is being evaluated for its effectiveness to accurately classify an indeterminate renal mass as ccRCC or non-cancerous, when compared to CT/MRI imaging and histopathology. Secondary endpoints include sensitivity, specificity, and the positive and predictive value of ITM-94 PET/CT imaging compared to histopathology. This study arm is expected to enroll approximately 36 patients at around 15 clinical sites across the EU, US and Australia.
' The early results from the Gallium-68 CAIX PET/CT diagnostic are remarkable to date. I believe ITM-94 has the potential to change the way urologists and oncologists diagnose and stage patients with clear cell renal cell carcinoma, improving accuracy and reducing the need for biopsies. I have not seen a tracer with a similar profile since the PSMA PET/CT was established,' added Prof. Michael Hofman, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter MacCallum Cancer Centre, Melbourne, Australia.
' Clear cell renal cell carcinoma is the most common form of kidney cancer, with more than 90% of cases overexpressing the CAIX encoding gene. As survival rates are highly dependent on the stage of progression, rapid and precise diagnosis is essential to provide patients with the best possible treatment options and therapeutic outcomes. ITM-94 has already demonstrated potential exceptional imaging qualities, including high tumor-to-background ratios and detecting lesions not visible by CT scan with a potential favorable safety profile. We look forward to exploring the full potential of the theranostic pair ITM-91/ITM-94 across this trial to characterize and treat CAIX expressing cancer cells, advancing the efficacy of targeted radiopharmaceutical therapies,' said Dr. Celine Wilke, Chief Medical Officer of ITM.
' With high-quality imaging and high tumor uptake, ITM-94 has already demonstrated potentially significant diagnostic capabilities in solid tumors. The data gathered in Part D of the trial will be instrumental to the further validation of this theranostic pair. We highly value our partnership with ITM, which will continue to advance the rapid progression of these novel radio-diagnostics and -therapeutics through the clinic,' said Angela Zubel, Chief Development Officer, Research & Development at Debiopharm.
About the Phase 1/2 ITM-91/ITM-94 Trial
The five-part clinical trial (NCT05706129) is designed to assess the safety and tolerability, imaging characteristics, and efficacy of the theranostic pair ITM-91/ITM-94 in patients with unresectable, locally advanced or metastatic solid tumors. In Part A of the trial, ITM-94 demonstrated exceptional tumor imaging characteristics, with a high tumor-to-background ratio and a favorable tolerability profile in patients with confirmed ccRCC, with results published in the Journal of Nuclear Medicine. Part B, which is ongoing, is assessing escalating doses of the therapeutic agent, ITM-91, in patients whose tumors show high uptake of the imaging tracer. Based on the recommended dose from Part B, Part C of the trial will assess the safety and preliminary efficacy of ITM-91 in patients with ccRCC, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma and potentially other tumor types. In addition to the newly initiated Part D, Part E will assess ITM-94 uptake in other tumors. ITM will assume full sponsorship of the program from Debiopharm once the transfer is completed.
About ITM-91/ITM-94 (Debio 0228/ 0328)
ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM. ITM-94 ([68Ga]Ga-DPI-4452) is a PET imaging agent that may be used independently and is designed to identify patients whose cancers overexpress CAIX. Once identified, these patients may be treated with the lutetium-labelled radioligand, ITM-91 ([177Lu]Lu-DPI-4452), which delivers targeted radiation to the tumor with the aim to destroy it from the inside.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
Debiopharm's commitment to patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com. We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews or on LinkedIn.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: [email protected]
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: [email protected]
Debiopharm Contact
Dawn Bonine - Head of Communications
[email protected]
Tel: +41 (0)21 321 01 11
Attachment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bolton cancer choir seeking new treasurer - 'not easy to replace'
A Bolton cancer choir is seeking to replace their treasurer who is stepping down after nearly eight years of dedicated service. Bolton Cancer Voices, which supports cancer patients and survivors through song, is searching for a new treasurer following the departure of Emma Willder. Ms Willder has been described as having made an 'invaluable contribution' to the choir during her time in the voluntary position. Karen Elliott, founder and chair of Bolton Cancer Voices, said: "Emma has been an absolute joy to work with and has made an invaluable contribution to the life of the choir. "We are desperately sorry that she's stepping down and tremendously grateful for all she's done over the years. "We have been extremely fortunate to have had someone with Emma's background on board, who both professionally and personally, has been a perfect fit for us. "She certainly won't be easy to replace." The group, formed in 2012, offers a supportive environment for people affected by cancer to enjoy singing together. It is open to anyone who has received a cancer diagnosis at any time. READ MORE: First look at new gothic horror filmed in Bolton as date set for when it will screen New jobs after supermarket gets green light to open -despite objection from Lidl The treasurer role is central to the choir's operations, requiring financial skills as well as a commitment to its mission. Ms Elliott said: "The treasurer plays an integral role in our organisation and it's important to us that that person feels passionate and invested in being part of Bolton Cancer Voices." To enquire about the role, contact Karen on 01204 595562 or email boltoncancervoices@
Bloomberg
an hour ago
- Bloomberg
BMW to Meet Investors as Weak China Sales Overshadow EV Strategy
BMW AG executives will likely face tough questions this week about worsening sales in China and the impact of global trade tensions when they sit down with investors and analysts in Munich. The two-day meeting, which starts Tuesday, comes a week after the German automaker reported a 14% second-quarter sales drop in China, where local manufacturers led by BYD Co. dominate on electric vehicles. The announcement followed BMW's worst first-quarter sales performance in the country since 2020.
CBS News
7 hours ago
- CBS News
Breakthroughs in cancer treatment spare Long Island teen from leg amputation
Breakthroughs in a rare cancer treatment are helping a New York woman conquer an aggressive bone tumor. Doctors at Cohen Children's Medical Center say a state-of-the-art surgery for osteosarcoma means the Long Island college student's leg will not have to be amputated. A devastating diagnosis Kelly Mullooly, a University of New Haven honors college freshman and student-athlete, presumed her constant knee pain was from too many gym workouts and rigorous cheer team activities. After the Massapequa-native started feeling it in December, doctors initially advised physical therapy. But nothing helped and she knew something wasn't right. "It was a very overwhelming time and a very scary time," she said. While home for spring break, Mullooly and her family insisted on more medical testing. They sought doctors at a different hospital -- Cohen Children's Medical Center. She went there for an MRI and doctors came back with devastating news. "That same day they found the tumor, and from there everything has just been a complete whirlwind," Mullooly said. "So fast-moving, with biopsies and doctors appointments, and within that week I was diagnosed with osteosarcoma." "Because this is a very aggressive tumor, we have to move very quickly with chemotherapy and treatment," Dr. Carolyn Fein Levy, of Cohen Children's Medical Center, said. Life-altering decisions and surgery Crissy Mullooly said she was in awe of her daughter, who remained brave and stoic while having to make life-altering decisions. "It's amazing because it's a lot to ask an 18-year-old at the time, now she's 19, to have gone through," she said. As part of the treatment, Mullooly underwent future fertility planning in which her eggs were harvested prior to chemotherapy. "They immediately had a plan for me and that was very comforting," she said. "She had what is called limb-sparing surgery where we take out a piece of the bone and replace with a prostheses in order to save her leg," Levy said. Mullooly's cancerous bone was removed and replaced with a metal knee. The surgery also saved her life. "We want her to be able to live the rest of her life without a sarcoma, without any cancer and to be able to do everything she wants to do," Dr. Howard Goodman said. "Not that everything will go back to normal, but everything will be a new normal," Mullooly said. As she completes chemotherapy, she's filled with optimism and ready to rejoin UNH and the cheer team later next year. Before limb-sparing surgery, a patient with osteosarcoma would have needed their leg amputated. They also would have continued living with the risk of the cancer returning.
